Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor. = Tratamiento de la enfermedad linfoproliferativa post-trasplante renal con Rituximab y conversión a inhibidor m-TOR [documento electrónico] / John Fredy Nieto Ríos, ; Catalina Ocampo Kohn, ; Lina Maria Serna Higuita, ; Arbey Aristizabal Álzate, ; Gustavo Adolfo Zuluaga Valencia, ; Kenny Mauricio Gálvez Cárdenas,  . - 2016.
Obra : Colombia Médica

Idioma : Inglés (eng)

Palabras clave :	Post-transplantation  lymphoproliferative disorders  kidney transplantation  rituximab  M-TOR inhibitors
Resumen :	Background: Post-transplantation lymphoproliferative disorders are serious complications of organ transplantation which treatment is not yet standardized. Objective: To describe the clinical response, overall and graft survival of patients in our center with this complication after kidney transplantation, which received rituximab as part of their treatment as well as conversion to m-TOR. Methods: Retrospective study, which included patients, diagnosed with post-transplant lymphoproliferative disorders after kidney transplantation from January 2011 to July 2014. Results: Eight cases were found with a wide spectrum of clinical presentations. Most had monomorphic histology, 85% were associated with Epstein-Barr virus, 25% of patients had tumor involvement of the renal graft, and 12.5% had primary central nervous system lymphoma. All patients were managed with reduction of immunosuppression, conversion to m-TOR (except one who lost the graft at diagnosis) and rituximab-based therapy. The overall response rate was 87.5% (62.5% complete response, 25% partial response). Survival was 87.5% with a median follow-up of 34 months. An additional patient lost the graft, with chronic nephropathy already known. All the remaining patients had stable renal function. Conclusions: There are no standardized treatment regimens for lymphoproliferative disorders after kidney transplantation, but these patients an be managed successfully with reduction of immunosuppression, conversion to m-TOR and rituximab-based schemes.
Mención de responsabilidad :	John Fredy Nieto-Rios, Sandra Milena Gómez de Los Ríos, Lina María Serna-Higuita, Catalina Ocampo-Kohn, Arbey Aristizabal-Alzate, Kenny Mauricio Gálvez-Cárdenas, Gustavo Adolfo Zuluaga-Valencia
Referencia :	Colomb Med (Cali). 2016 Dec 30;47(4):196-202.
PMID :	28293043
Derechos de uso :	CC BY
En línea :	http://colombiamedica.univalle.edu.co/index.php/comedica/article/view/1989
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4012